biostudies-literatureLipton RBNational Institute for Health Research (NIHR)e1365-e1377https://www.ebi.ac.uk/biostudies/studies/S-EPMC7274916biostudies-literatureUnknown94(13)<h4>Objective</h4>To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM).<h4>Methods</h4>The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12.<h4>Results</h4>Among treated participants (n = 1,072), baseline mean number of MMDs was ≈16.1 across groups. Treatment with eptinezumab 100 and 300 mg was associateNeurologyEfficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.PMC7274916NF-SI-0616-10031NIHR201369Allan BBiondi DMPederson SLipton RBHirman JGoadsby PJSmith JSchaeffler BACady RfalseEfficacy and safety of eptinezumab in patients with chronic migraine: PROMISE-2.<h4>Objective</h4>To evaluate the efficacy and safety of eptinezumab, a humanized anti-calcitonin gene-related peptide monoclonal antibody, in the preventive treatment of chronic migraine (CM).<h4>Methods</h4>The Prevention of Migraine via Intravenous ALD403 Safety and Efficacy-2 (PROMISE-2) study was a phase 3, multicenter, randomized, double-blind, placebo-controlled, parallel-group study. Adults with CM were randomly assigned to receive IV eptinezumab 100 mg, eptinezumab 300 mg, or placebo administered on day 0 and week 12. The primary endpoint was change from baseline in mean monthly migraine days (MMDs) over weeks 1 to 12.<h4>Results</h4>Among treated participants (n = 1,072), baseline mean number of MMDs was ≈16.1 across groups. Treatment with eptinezumab 100 and 300 mg was associate2020-01-01T00:00:00Z2020 Mar2025-04-19T11:51:19.443Z2020-06-27T07:28:42ZS-EPMC72749163220965010.1212/WNL.0000000000009169